NP
ABBV icon

NorthRock Partners’s AbbVie ABBV Stock Holding History

NorthRock Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
66,702
+1,946
+3% +$419K 0.24% 63
2026
Q1 		$14.1M Buy
64,756
+888
+1% +$197K 0.23% 65
2025
Q4 		$14.6M Sell
63,868
-19,199
-23% -$4.37M 0.25% 63
2025
Q3 		$19.2M Buy
83,067
+6,270
+8% +$1.28M 0.35% 52
2025
Q2 		$14.3M Buy
76,797
+1,759
+2% +$327K 0.37% 35
2025
Q1 		$15.7M Buy
75,038
+2,174
+3% +$423K 0.53% 29
2024
Q4 		$12.9M Sell
72,864
-1,139
-2% -$209K 0.42% 35
2024
Q3 		$14.6M Sell
74,003
-53
-0.1% -$9.89K 0.48% 30
2024
Q2 		$12.7M Sell
74,056
-101
-0.1% -$16.7K 0.48% 29
2024
Q1 		$13.5M Buy
74,157
+1,299
+2% +$224K 0.52% 30
2023
Q4 		$11.3M Buy
72,858
+49,769
+216% +$7.26M 0.47% 33
2023
Q3 		$3.44M Buy
23,089
+1,993
+9% +$293K 0.36% 34
2023
Q2 		$2.84M Sell
21,096
-5,239
-20% -$768K 0.31% 35
2023
Q1 		$4.2M Buy
26,335
+885
+3% +$135K 0.45% 30
2022
Q4 		$4.11M Sell
25,450
-4,675
-16% -$717K 0.47% 28
2022
Q3 		$4.04M Sell
30,125
-1,957
-6% -$281K 0.47% 29
2022
Q2 		$4.91M Sell
32,082
-3,434
-10% -$525K 0.51% 24
2022
Q1 		$5.76M Sell
35,516
-35,487
-50% -$5.15M 0.52% 26
2021
Q4 		$9.61M Buy
71,003
+2,421
+4% +$286K 0.72% 19
2021
Q3 		$7.5M Buy
68,582
+3,529
+5% +$403K 0.61% 22
2021
Q2 		$7.33M Sell
65,053
-141
-0.2% -$15.9K 0.61% 22
2021
Q1 		$7.05M Sell
65,194
-1,086
-2% -$116K 0.64% 21
2020
Q4 		$7.1M Buy
66,280
+1,902
+3% +$183K 0.7% 22
2020
Q3 		$5.64M Buy
64,378
+200
+0.3% +$18.8K 0.63% 23
2020
Q2 		$6.3M Buy
64,178
+2,476
+4% +$218K 0.75% 21
2020
Q1 		$4.7M Buy
61,702
+25,097
+69% +$2.14M 0.66% 27
2019
Q4 		$3.24M Buy
36,605
+13,151
+56% +$1.09M 0.34% 52
2019
Q3 		$1.78M Buy
+23,454
New +$1.61M 0.24% 63

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

NorthRock Partners's ABBV Position: Q2 2026 in Review

NorthRock Partners increased its AbbVie (ABBV) stake by 3% in Q2 2026, buying an estimated $419K and bringing the position to 66,702 shares worth $16.8M. The position accounts for 0.24% of the portfolio, ranked #63.

NorthRock Partners first reported a position in ABBV in Q3 2019 and has held it in 28 quarters since. The position peaked at $19.2M in Q3 2025. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • NorthRock Partners held 66,702 shares of AbbVie worth $16.8M as of Q2 2026.
  • NorthRock Partners bought 1,946 AbbVie shares in Q2 2026, an estimated $419K.
  • AbbVie made up 0.24% of NorthRock Partners's portfolio in Q2 2026, its #63 holding.
  • NorthRock Partners first reported a position in AbbVie in Q3 2019 and has held it in 28 quarters since.
  • NorthRock Partners's AbbVie position peaked at $19.2M in Q3 2025.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on NorthRock Partners's 13F filing for Q2 2026, filed 11 Aug 2026.